A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
Study sponsor: Emergent BioSolutions
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2014-02Actual
Enrollment · participants168Actual
Source updated2024-03-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.